Novo Nordisk (NVO) Fell Following a Profit Warning Release

Core Insights - Parnassus Value Equity Fund reported a net return of 7.46% for Q3 2025, outperforming the Russell 1000 Value Index which returned 5.33% during the same period [1] - The fund adjusted its portfolio by reducing its weight in the IT sector and increasing holdings in the Health Care sector [1] Company Specifics - Novo Nordisk A/S (NYSE:NVO) experienced a one-month return of -0.36% and a 52-week decline of 53.82%, closing at $47.77 per share with a market capitalization of $212.265 billion on December 17, 2025 [2] - The decline in Novo Nordisk's shares was attributed to a profit warning amid rising competition in the obesity drug market, although the fund maintains confidence in the company's long-term pipeline and potential catalysts from its oral GLP-1 launch [3] - At the end of Q3 2025, 50 hedge fund portfolios held Novo Nordisk A/S, an increase from 45 in the previous quarter, indicating growing interest despite the recent challenges [3]